keyword
MENU ▼
Read by QxMD icon Read
search

Erythropoeitin resistance

keyword
https://www.readbyqxmd.com/read/28457029/role-of-ace-and-il-1%C3%AE-gene-polymorphisms-in-erythropoeitin-hyporesponsive-patients-with-chronic-kidney-disease-with-anemia
#1
N Nand, A R Deshmukh, S Joshi, M P Sachdeva, Sakthivel
BACKGROUND: Hyporesponse to erythropoietin is a common problem seen in around 5-10% of patients. Recently the focus from these remediable factors has been shifted to the non-modifiable innate factors i.e polymorphism of ACE and IL-1B gene and studies have shown that DD genotype and IL-1B CC genotype have lower erythropoietin requirement. The aim of our study was to evaluate the role of ACE and IL-1B gene polymorphisms in erythropoietin hyporesponse in CKD patients with anemia. METHODS: A total of 50 patients were selected...
February 2017: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/25758589/evaluation-of-multi-neuroprotective-effects-of-erythropoietin-using-cisplatin-induced-peripheral-neurotoxicity-model
#2
Nivin Sharawy, Laila Rashed, Magdy Fouad Youakim
Cisplatin (CDDP) is severely neurotoxic anti-neoplastic drug that causes peripheral neuropathies with clinical signs known as chemotherapy-induced peripheral neurotoxicity. The ameliorating effects of erythropoeitin on cisplatin-induced neuropathy, which seem to be mediated by enhancing the cell resistance to side effects of cisplatin rather than by influencing the formation or repair rates of cisplatin-induced cross-links in the nuclear DNA, had been previously reported. The main objective of our study is to investigate the roles of nitro-oxidative stress, nuclear factor kappa B (NFκB) gene expressions and TNF levels on the previous reported erythropoietin anti-apoptotic neuroprotective effects during cisplatin induced neurotoxicity...
April 2015: Experimental and Toxicologic Pathology: Official Journal of the Gesellschaft Für Toxikologische Pathologie
https://www.readbyqxmd.com/read/23734775/how-can-erythropoeitin-stimulating-agent-use-be-reduced-in-chronic-dialysis-patients-can-reduction-of-inflammation-improve-esa-dose-response
#3
Csaba P Kovesdy
No abstract text is available yet for this article.
September 2013: Seminars in Dialysis
https://www.readbyqxmd.com/read/23734745/how-can-erythropoeitin-stimulating-agent-use-be-reduced-in-chronic-dialysis-patients-the-forgotten-adjunct-therapy-the-link-between-esa-use-and-control-of-hyperparathyroidism-in-chronic-kidney-disease
#4
REVIEW
https://www.readbyqxmd.com/read/18497705/darbepoetin-alpha-a-long-acting-erythropoeitin-derivate-does-not-alter-lps-evoked-myocardial-depression-and-gene-expression-of-bax-bcl-xs-bcl-xl-bcl-2-and-tnf-alpha
#5
Peter Brendt, Ulrich Frey, Michael Adamzik, Simon T Schäfer, Jürgen Peters
Darbepoetin alpha (DA), a long-acting erythropoietin derivative stimulating erythropoiesis, can, by antiapoptotic effects, mitigate myocardial I/R injury. We tested the hypothesis that DA treatment improves left ventricular function (LV) in LPS evoked cardiomyopathy and alters gene expression of apoptosis-regulating proteins (Bcl-XL, Bcl-2, Bax, and Bcl-Xs) and TNF-alpha. In a prospective, controlled, randomized study in Lewis rats (n = 56; 8 groups), myocardial depression was evoked by LPS administration (serotype O127:B8; 10 mg/kg, i...
January 2009: Shock
https://www.readbyqxmd.com/read/17890929/increased-vascular-alpha1-adrenergic-sensitivity-in-patients-with-renal-failure-receiving-recombinant-erythropoeitin
#6
Ademola K Abiose, Wilbert S Aronow, Heitor Moreno, Chandra K Nair, Terrence F Blaschke, Brian B Hoffman
End stage renal disease (ESRD) is associated with altered hemodynamic regulation as a result of the pathophysiology or treatment of renal failure. Hypertension, common among dialysis patients, is a recognized complication of recombinant human erythropoietin (rHuEPO) therapy. We determined vascular adrenergic and nitric-oxide-mediated responsiveness in 7 patients with established ESRD on rHuEPO treatment and in 13 healthy volunteers using the dorsal hand vein technique. Sensitivity to the alpha1-adrenergic selective agonist phenylephrine was significantly increased in patients with ESRD on rHuEPO...
September 2007: American Journal of Therapeutics
https://www.readbyqxmd.com/read/14531778/erythropoeitin-dose-variation-in-different-facilities-in-different-countries-and-its-relationship-to-drug-resistance
#7
MULTICENTER STUDY
Roger N Greenwood, Claudio Ronco, Fiorella Gastaldon, Alessandra Brendolan, Peter Homel, Len Usvyat, Lenore Bruno, Mary Carter, Nathan W Levin
BACKGROUND: The correction of anemia using erythropoeitin (EPO) is accorded high priority in the management of patients undergoing hemodialysis (HD). Target hemoglobin (Hb) levels have been established in many countries. Following an observation that the mean facility EPO dose in a chain of facilities in the United States varied by more than two-fold, an examination of the practice of anemia correction in other settings was carried out. METHODS: We reviewed demographic and laboratory parameters in prevalent HD patients in 50 United States facilities and in a single HD facility in Vicenza, Italy...
November 2003: Kidney International. Supplement
https://www.readbyqxmd.com/read/12803508/low-dose-intravenous-ascorbic-acid-for-erythropoietin-hyporesponsive-anemia-in-diabetic-hemodialysis-patients-with-iron-overload
#8
COMPARATIVE STUDY
Chun-Liang Lin, Po-Yaur Hsu, Huan-Yu Yang, Chiu-Ching Huang
BACKGROUND: Recent report demonstrates that inadequate iron mobilization and defective iron utilization may cause recombinant erythropoieitin (rEPO) hyporesponsiveness in hemodialysis (HD) patients with iron overload. The effect of intravenous ascorbic acid (IVAA) in HD patients selected on the basis of iron overload and EPO resistance also has been proven. However, it is uncertain whether IVAA still works in diabetic ESRD patients with hyperferritinemia. Therefore, the aim of this study focusing on diabetic ESRD patients was to analyze the potential effect of low dose IVAA on improvement of anemia and erythropoiesis-related parameters when compared with control period...
May 2003: Renal Failure
https://www.readbyqxmd.com/read/1824502/-molecular-genetic-of-growth-hormone-resistance-syndrome
#9
REVIEW
S Amselem, M L Sobrier, P Duquesnoy, M Goossens
The cloning of a putative growth hormone receptor (GH-R) cDNA has opened new approaches for the understanding of the molecular basis of GH insensitivity in humans. This molecule belongs to a new class of transmembrane receptors including prolactin, granulocyte-macrophage colony stimulating factor, erythropoeitin and some interleukin receptors. Although the domains responsible for signal transduction have not yet been identified, the molecular study of a GH-resistance syndrome described by Laron et al. should provide insight into the structure-function relationships of the GH-R and related receptors...
1991: Annales D'endocrinologie
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"